We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Assays Evaluated for Influenza in Blood Donors

By LabMedica International staff writers
Posted on 26 Mar 2012
Sensitive molecular assays have been used to screen blood donors for the presence of influenza viremia via ribonucleic acid (RNA) testing.

Several influenza RNA amplification assays, including transcription-mediated amplification (TMA) and two reverse-transcription polymerase chain reaction (RT-PCR) assays were evaluated and used to test donor samples. More...


Scientists at the Blood Systems Research Institute (San Francisco, CA, USA) collaborating with other institutes, retrospectively tested samples from 478 subjects drawn at sites with high influenza activity. They collected prospective samples from 1,004 blood donors who called their donation center within three days of donation complaining of influenza-like illness (ILI). The plasma collected on the day of donation for these subjects was tested.

A number of different influenza RNA detection assays were evaluated prior to testing donor samples, all of which were previously shown to detect commonly circulating contemporary influenza viruses. The MGB Alert system (Epoch Biosciences; Bothell, WA, USA) uses RNA extraction followed by RT-PCR. The Prodesse ProFlu-1 assay (Gen-Probe, San Diego, CA, USA) uses RNA extraction followed by a TaqMan-based, real-time RT-PCR amplification targeting the influenza A matrix gene. Transcription-mediated amplification, also from Gen-Probe, uses a target-capture probe for influenza A matrix gene during RNA extraction followed by isothermal amplification using bacteriophage T7 RNA polymerase and Moloney murine leukemia virus reverse transcriptase. The assays were validated on spiked samples and an animal model.

Of the repository samples, two of 478 plasma samples were initially reactive, but were not repeat reactive by influenza TMA. Of blood donors reporting ILI symptoms after donation, only one of 1,004 samples was TMA initially reactive, but was not repeat reactive, while all samples were nonreactive by RT-PCR testing. The authors reported that they failed to detect influenza A viremia using very sensitive tests in blood samples from donors collected during periods of high influenza transmission in the community, with the majority of the tested donors reporting symptoms of influenza-like illness. The preponderance of evidence from this and other studies thus suggests that influenza viremia is at most an exceedingly rare event in blood donors, who are healthy at the time of donation, and that influenza viremia only occurs in subjects with moderate to severe disease. The study was published on March 15, 2012, in the Journal of Infectious Diseases.

Related Links:

Blood Systems Research Institute
Epoch Biosciences
Gen-Probe



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Electrolyte Analyzer
BKE-B
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.